These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
464 related articles for article (PubMed ID: 20458041)
61. U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. Lemery SJ; Zhang J; Rothmann MD; Yang J; Earp J; Zhao H; McDougal A; Pilaro A; Chiang R; Gootenberg JE; Keegan P; Pazdur R Clin Cancer Res; 2010 Sep; 16(17):4331-8. PubMed ID: 20601446 [TBL] [Abstract][Full Text] [Related]
62. Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia. Robak T; Blonski JZ; Robak P Semin Oncol; 2016 Apr; 43(2):280-90. PubMed ID: 27040707 [TBL] [Abstract][Full Text] [Related]
63. Improving the treatment outcome of patients with chronic lymphocytic leukemia through targeted antibody therapy. Stephens DM; Byrd JC Hematol Oncol Clin North Am; 2013 Apr; 27(2):303-27. PubMed ID: 23561475 [TBL] [Abstract][Full Text] [Related]
64. Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia: from uncertainties to promises. Bagacean C; Zdrenghea M; Tempescul A; Cristea V; Renaudineau Y Immunotherapy; 2016 May; 8(5):569-81. PubMed ID: 27140410 [TBL] [Abstract][Full Text] [Related]
65. Novel monoclonal antibodies for the treatment of chronic lymphocytic leukemia. Robak T Curr Cancer Drug Targets; 2008 Mar; 8(2):156-71. PubMed ID: 18336199 [TBL] [Abstract][Full Text] [Related]
66. Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab. Sacchi S; Federico M; Dastoli G; Fiorani C; Vinci G; Clò V; Casolari B Crit Rev Oncol Hematol; 2001 Jan; 37(1):13-25. PubMed ID: 11164715 [TBL] [Abstract][Full Text] [Related]
67. Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement/rituximab interactions & clinical results in refractory CLL. Klepfish A; Gilles L; Ioannis K; Rachmilewitz EA; Schattner A Ann N Y Acad Sci; 2009 Sep; 1173():865-73. PubMed ID: 19758239 [TBL] [Abstract][Full Text] [Related]
72. Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. Lapalombella R; Yu B; Triantafillou G; Liu Q; Butchar JP; Lozanski G; Ramanunni A; Smith LL; Blum W; Andritsos L; Wang DS; Lehman A; Chen CS; Johnson AJ; Marcucci G; Lee RJ; Lee LJ; Tridandapani S; Muthusamy N; Byrd JC Blood; 2008 Dec; 112(13):5180-9. PubMed ID: 18772452 [TBL] [Abstract][Full Text] [Related]
73. Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties. Rafiq S; Butchar JP; Cheney C; Mo X; Trotta R; Caligiuri M; Jarjoura D; Tridandapani S; Muthusamy N; Byrd JC J Immunol; 2013 Mar; 190(6):2702-11. PubMed ID: 23418626 [TBL] [Abstract][Full Text] [Related]
74. Distinct in vitro sensitivity of p53-mutated and ATM-mutated chronic lymphocytic leukemia cells to ofatumumab and rituximab. Sebejova L; Borsky M; Jaskova Z; Potesil D; Navrkalova V; Malcikova J; Sramek M; Doubek M; Loja T; Pospisilova S; Mayer J; Trbusek M Exp Hematol; 2014 Oct; 42(10):867-74.e1. PubMed ID: 24970561 [TBL] [Abstract][Full Text] [Related]
75. Novel humanized anti-CD20 monoclonal antibodies with unique germline VH and VL gene recruitment and potent effector functions. Nishida M; Teshigawara K; Niwa O; Usuda S; Nakamura T; Ralph P; Newman R; Padlan EA Int J Oncol; 2008 Jun; 32(6):1263-74. PubMed ID: 18497988 [TBL] [Abstract][Full Text] [Related]
76. [Rituximab, a chimeric anti-CD20 monoclonal antibody, in the treatment of B-cell lymphoma]. Tobinai K Gan To Kagaku Ryoho; 2002 Mar; 29(3):473-80. PubMed ID: 11915743 [TBL] [Abstract][Full Text] [Related]
78. Engineered anti-CD20 antibodies with enhanced complement-activating capacity mediate potent anti-lymphoma activity. Natsume A; Shimizu-Yokoyama Y; Satoh M; Shitara K; Niwa R Cancer Sci; 2009 Dec; 100(12):2411-8. PubMed ID: 19758394 [TBL] [Abstract][Full Text] [Related]
79. The European Medicines Agency review of ofatumumab (Arzerra®) for the treatment of chronic lymphocytic leukemia in patients refractory to fludarabine and alemtuzumab: summary of the scientific assessment of the European medicines agency committee for medicinal products for human use. Gravanis I; Ersbøll J; Skovlund E; Abadie E; Marty M; Pignatti F Oncologist; 2010; 15(12):1335-43. PubMed ID: 21156732 [TBL] [Abstract][Full Text] [Related]
80. The latest developments with anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia. Evers M; Jak M; Leusen JHW Expert Opin Biol Ther; 2018 Sep; 18(9):973-982. PubMed ID: 30084674 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]